Protocol Ledger

NCT04302103 · Phase II · COMPLETED

A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

Interventional Phase II clinical trial protocol NCT04302103 sponsored by RemeGen Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-07 Enrollment: 29 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04302103
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)29 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04302103
Protocol FieldVerified Registry Value
NCT IdentifierNCT04302103
Consolidated Lead SponsorRemeGen Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment29 participants (ACTUAL)
Registered Start Date2020-07-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04302103
Hospital Research SiteLocationSite Profile
Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->
Jiangxi Provincial People's HospitalNanchang, ChinaOpen Hospital Dossier ->
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI